Table 1 Patient cohort characteristics (n = 604)
Variable | No. (%) or median (IQR) |
|---|---|
Gender | |
Male | 274 (45.5%) |
Female | 330 (54.6%) |
Primary Cancer | |
Lung | 107 (17.7%) |
Breast | 187 (31%) |
Melanoma | 8 (1.3%) |
Renal cell carcinoma | 7 (1.2%) |
Gastrointestinal | 42 (7%) |
Gynecologic | 17 (2.8%) |
Prostate | 110 (18.2%) |
Lymphoma | 6 (1%) |
Myeloma | 6 (1%) |
Central nervous system | 25 (4.1%) |
Head & neck | 42 (7%) |
Sarcoma/connective tissue | 14 (2.3%) |
Non-melanoma skin cancer | 20 (3.3%) |
Leukemia | 1 (0.2%) |
Non-prostate Genitourinary | 11 (1.8%) |
Endocrine | 1 (0.2%) |
Previous SARS-CoV-2 PCR test | |
Yes | 204 (33.8%) |
No | 400 (66.2%) |
If previous SARS-CoV-2 test, number | |
1 | 162 (79.4%) |
2 | 36 (17.6%) |
3 | 6 (2.9%) |
If previous SARS-CoV-2 test, result | |
Negative | 204 (100%) |
Systemic therapy within 3 months prior to RT | |
Yes | 257 (42.5%) |
No | 347 (57.5%) |
Systemic therapy concurrent with RT | |
Yes | 167 (27.6%) |
No | 437 (72.4%) |
Patient admission status | |
Inpatient | 27 (4.5%) |
Outpatient | 577 (95.5%) |
Age (years) | 65 (56–73) |
RT duration (weeks) | 4 (1.6–6.1) |
RT number of fractions | 15 (5–25) |